The news surrounding CareDx's upward earnings revision examines the clinical data from the KOAR paper, the company's long-term plan and the stock's valuation, with future developments being closely watched.
The KOAR paper showed an association between early trends in dd-cfDNA measured by AlloSure Kidney and 3-year graft outcomes in more than 1,100 transplant patients at 56 facilities. Persistent or delayed increases were reported to be associated with the incidence of dysfunction, rejection and graft loss, and could also affect test adoption and reimbursement stability.
CareDx is said to have raised its latest full-year revenue outlook for 2026, while its business plan sets a target of approximately US$701 million in revenue and US$80.6 million in profit by 2029. This includes annual revenue growth of approximately 12.1% and an assumption that profit margins will remain at current levels.
From a market valuation perspective, fair value indicates approximately 19% upside from the current share price, although that upside could narrow in the future. From another perspective, a cautious valuation estimates 2029 revenue at approximately US$651.5 million and profit at approximately US$44.2 million, implying fair value approximately 10% below the market price.
A reassessment of the valuation is cited as a short-term risk to the share price, while the underlying factors driving test demand and margins are considered important over the longer term. The article is not intended to encourage investment in CareDx, but solely to organize the relevant data and estimates.